

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 Caplus coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change
NEWS 22 DEC 17 USPATOLD added to additional database clusters
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27 DEC 17 CA/Capplus enhanced with new custom IPC display formats
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Updated Search

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 23:40:03 ON 06 JAN 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 23:40:15 ON 06 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JAN 2008 HIGHEST RN 960040-46-4
DICTIONARY FILE UPDATES: 4 JAN 2008 HIGHEST RN 960040-46-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> file casreact		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.52	5.73

FILE 'CASREACT' ENTERED AT 23:47:18 ON 06 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 5 Jan 2008 VOL 148 ISS 2

Updated Search

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*      CASREACT now has more than 13.8 million reactions      *
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\acvg.str

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 23:48:06 FILE 'CASREACT'
SCREENING COMPLETE - 60 REACTIONS TO VERIFY FROM 8 DOCUMENTS

100.0% DONE 60 VERIFIED 0 HIT RXNS 0 DOCS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED VERIFICATIONS: 736 TO 1664
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1 (0 REACTIONS)

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'CASREACT' IS 117.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 23:48:11 FILE 'CASREACT'
SCREENING COMPLETE - 1127 REACTIONS TO VERIFY FROM 175 DOCUMENTS

100.0% DONE 1127 VERIFIED 43 HIT RXNS 9 DOCS
SEARCH TIME: 00.00.01

L3 9 SEA SSS FUL L1 (43 REACTIONS)

=> s l3 and shapiro, r?/au
 50 SHAPIRO, R?/AU
L4 0 L3 AND SHAPIRO, R?/AU

=> d l3, ibib abs fhit, 1-9

L3 ANSWER 1 OF 9 CASREACT COPYRIGHT 2008 ACS on STN
*ACCESSION NUMBER: 144:212761 CASREACT
TITLE: Preparation of (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-
 3,6-diazabicyclo[3.2.0]heptane as a nicotinic
 acetylcholine receptor ligand useful as an effective
 analgesic agent
INVENTOR(S): Buckley, Michael J.; Ji, Jianguo; Zhang, Geoff G. Z.;
 Henry, Rodger F.; Wang, Weili W.; Wayne, Gregory S.;
 Li, Wenke; Towne, Timothy B.; Wittenberger, Steven J.;

Updated Search


Hannick, Steven M.; Kotecki, Brian J.; Macri, Bryan S.; Robbins, Timothy A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 898,441.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006035936	A1	20060216	US 2005-176087	20050707
US 2004242644	A1	20041202	US 2004-851917	20040521
US 2005261348	A1	20051124	US 2004-898441	20040723
PRIORITY APPLN. INFO.:			US 2004-851917	20040521
			US 2004-898441	20040723
			US 2003-473530P	20030527


AB The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane (I) and salts thereof, methods for their preparation and their use to treat pain and other disorders associated with the nicotinic acetylcholine receptor. Compared to related analogs, I is a potent analgesic with reduced side effect liability. Compound I was prepared in 10 steps starting from 2-hydroxy-5-nitropyridine and involving intermediates 3-chloro-2-hydroxy-5-nitropyridine, 2,3-dichloro-5-nitropyridine, (5,6-dichloropyridin-3-yl)(2,2-dimethoxyethyl)amine, allyl(5,6-dichloropyridin-3-yl)(2,2-dimethoxyethyl)amine, 2-(S)-hydroxyamino-2-phenylethanol, 2-[(allyl)(5,6-dichloropyridin-3-yl)amino]acetaldehyde, (3aS,6aS)-2-[5-(5,6-dichloropyridin-3-yl)hexahydropyrrolo[3,4-c]isoxazol-1-yl]-2-(S)-phenylethanol, (3aS,6aS)-5-(5,6-dichloropyridin-3-yl)hexahydropyrrolo[3,4-c]isoxazole and [(3S,4S)-4-amino-1-(5,6-dichloropyridin-3-yl)pyrrolidin-3-yl]methanol.

RX(270) OF 404 COMPOSED OF REACTION SEQUENCE RX(18), RX(19)
 AND REACTION SEQUENCE RX(4), RX(5), RX(6), RX(8), RX(10),
 RX(11), RX(12), RX(13), RX(14), RX(19)


... BB ==> BD...
 ...K + U + V + 2 AC + AI + BD ==> BH




START NEXT REACTION SEQUENCE




K




U




V




AC



AC




AI



BD

10
STEPS
→



BH

RX(18) RCT BB 98121-41-6

STAGE(1)

RGT BE 10035-10-6 HBr, BF 7632-00-0 NaNO2

SOL 7732-18-5 Water

CON SUBSTAGE(1) 60 minutes, 0 - 5 deg C

SUBSTAGE(2) 0 - 5 deg C

SUBSTAGE(3) 10 minutes, 0 - 5 deg C

STAGE(2)

RGT BG 7787-70-4 CuBr

SOL 7732-18-5 Water

CON 20 minutes

PRO BD 97966-00-2

RX(4)

RCT K 370880-75-4

RGT N 127-09-3 AcONa, O 5470-11-1 H2NOH-HCl

PRO M 370880-76-5

SOL 7732-18-5 Water, 75-05-8 MeCN

CON 20 hours, room temperature

RX(5)

RCT M 370880-76-5

Updated Search

STAGE(1)
 SOL 1330-20-7 Xylene
 CON 10 hours, reflux

 STAGE(2)
 RGT R 64-19-7 AcOH, S 7440-66-6 Zn
 CON SUBSTAGE(1) reflux -> 15 deg C
 SUBSTAGE(3) 3 hours, room temperature

 PRO Q 252770-09-5

 RX(6) RCT Q 252770-09-5, U 116-11-0

 STAGE(1)
 SOL 67-64-1 Me2CO
 CON overnight, room temperature

 STAGE(2)
 RCT V 611-71-2
 SOL 67-64-1 Me2CO
 CON SUBSTAGE(1) room temperature
 SUBSTAGE(2) 48 hours, room temperature

 PRO W 252770-03-9

 RX(8) RCT W 252770-03-9

 STAGE(1)
 RGT AE 7664-93-9 H2SO4
 SOL 7732-18-5 Water, 64-17-5 EtOH
 CON 16 hours, room temperature

 STAGE(2)
 RCT AC 24424-99-5
 RGT D 1310-73-2 NaOH
 SOL 7732-18-5 Water, 64-17-5 EtOH
 CON SUBSTAGE(1) room temperature, pH 10
 SUBSTAGE(2) 10 - 20 deg C
 SUBSTAGE(3) 4 hours, room temperature

 PRO AD 246510-69-0
 NTE stereoselective

 RX(10) RCT AD 246510-69-0, AI 124-63-0

 STAGE(1)
 RGT AK 121-44-8 Et3N
 SOL 75-09-2 CH2Cl2
 CON SUBSTAGE(1) 0.51 hours, -10 deg C
 SUBSTAGE(2) -10 deg C -> room temperature

 STAGE(2)
 RGT E 7732-18-5 Water

 PRO AJ 246510-70-3

 RX(11) RCT AJ 246510-70-3
 RGT AN 76-05-1 F3CCO2H
 PRO AM 799279-83-7
 SOL 75-09-2 CH2Cl2
 CON 1 hour, room temperature

RX(12) RCT AM 799279-83-7
 RGT D 1310-73-2 NaOH
 PRO AO 370881-43-9
 SOL 7732-18-5 Water, 64-17-5 EtOH
 CON SUBSTAGE(1) room temperature, pH 12
 SUBSTAGE(2) 1.5 hours, room temperature -> 60 deg C

RX(13) RCT AO 370881-43-9, AC 24424-99-5
 PRO AP 799279-84-8
 SOL 64-17-5 EtOH
 CON SUBSTAGE(1) 0.3 hours, room temperature
 SUBSTAGE(2) 0.5 - 1 hour, room temperature

RX(14) RCT AP 799279-84-8
 RGT AR 1333-74-0 H2
 PRO AQ 799279-81-5
 CAT 7440-05-3 Pd
 SOL 67-56-1 MeOH
 CON 10 hours, room temperature


RX(19) RCT AQ 799279-81-5, BD 97966-00-2
 RGT BI 161265-03-8 Phosphine, 1,1'-(9,9-dimethyl-9H-xanthene-4,5-diyl)bis[1,1-diphenyl-, BJ 865-48-5 NaOBu-t
 PRO BH 799279-86-0
 CAT 51364-51-3 Ph2-pentadienone Pd
 SOL 108-88-3 PhMe
 CON SUBSTAGE(1) room temperature
 SUBSTAGE(2) 2 hours, room temperature -> 90 deg C

L3 ANSWER 2 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 142:134428 CASREACT
 TITLE: The syntheses of 3-substituted 4-(pyridin-2-ylthio)indoles via Leimgruber-Batcho indole synthesis
 AUTHOR(S): Srisook, Ekaruth; Chi, Dae Yoon
 CORPORATE SOURCE: Department of Chemistry, Inha University, Incheon, 402-751, S. Korea
 SOURCE: Bulletin of the Korean Chemical Society (2004), 25(6), 895-899
 CODEN: BKCSDE; ISSN: 0253-2964
 PUBLISHER: Korean Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A new family of radioligands, 3-(amino- and hydroxymethyl)-4-(5-iodopyridin-2-ylthio)indoles, combining characteristically distinct moieties proven to impart successful binding ability in a variety of structurally diverse selective serotonin reuptake inhibitors recently published. Described in this article are the syntheses of 3-substituted 4-(5-iodopyridin-2-ylthio)-indoles, featuring successful adaptation of the modified Leimgruber-Batcho indole synthesis onto the key intermediate 1-(5-iodopyridin-2-ylthio)-2-methyl-3-nitrobenzene prepared from the nucleophilic aromatic substitution of chloropyridine with thiophenol.

RX(2) OF 97 ...H ==> C...



RX(2) RCT H 20511-12-0

STAGE(1)

RGT I 7647-01-0 HCl
SOL 7732-18-5 Water
CON 10 minutes, 0 deg C

STAGE(2)

RGT J 7632-00-0 NaNO₂, K 7758-89-6 CuCl
CON overnight, room temperature

PRO C 69045-79-0

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 141:366121 CASREACT

TITLE: Preparation of dibenzo[b,f]furan-1-carboxamides, 9H-carbazole-4-carboxamides, and dibenzo[b,d]thiophene-4-carboxamides as PDE4 inhibitors for the treatment of inflammatory and allergic disorders

INVENTOR(S): Gopalan, Balasubramanian; Gharat, Laxmikant Atmaram; Lakdawala, Aftab Dawoodbhai; Karaunakaran, Usha

PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Ltd., India

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089940	A1	20041021	WO 2004-IB355	20040211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MU00363	A	20050304	IN 2003-MU363	20030411
AU 2004228453	A1	20041021	AU 2004-228453	20040211
CA 2522023	A1	20041021	CA 2004-2522023	20040211
EP 1620429	A1	20060201	EP 2004-710093	20040211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

Updated Search

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK



BR 2004009747	A	20060509	BR 2004-9747	20040211
CN 1829711	A	20060906	CN 2004-80016048	20040211
JP 2006522789	T	20061005	JP 2006-506259	20040211
NZ 542882	A	20071026	NZ 2004-542882	20040211
US 2005027129	A1	20050203	US 2004-821642	20040409
US 7223789	B2	20070529		
MX 2005PA10948	A	20060531	MX 2005-PA10948	20051011
ZA 2005008240	A	20060531	ZA 2005-8240	20051012
NO 2005005316	A	20060111	NO 2005-5316	20051110
US 2007105854	A1	20070510	US 2006-536434	20060928
US 2007105855	A1	20070510	US 2006-536448	20060928

PRIORITY APPLN. INFO.:

IN 2003-MU363	20030411
US 2003-519967P	20031113
WO 2004-IB355	20040211
US 2004-821642	20040409

OTHER SOURCE(S): MARPAT 141:366121

GI




AB Title heterocyclic tricycles I [wherein R1-R3, R5, R6, Ra = independently H, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, (hetero)aryl, heterocyclyl(alkyl), etc.; R4 = NR5R6, heterocyclyl; Ar = (un)substituted aryl(alkyl), heterocyclyl, heteroaryl; X = O, SOO-2, NRA; Y = CONR7, NR7SOO-2, SOO-2NR7, NR7CO; R7 = H, OH, ORa, (un)substituted alkyl, aryl, heterocyclyl; P = O, S; m = 0-3; n = 1-4; and tautomers, regioisomers, stereoisomers, enantiomers, diastereomers, polymorphs, N-oxides, pharmaceutically acceptable salts, solvates, and compns. thereof] were prepared as phosphodiesterase type 4 (PDE4) inhibitors. For example, N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-aminodibenzo[b,f]furan-1-carboxamide (prepared in six steps from isovanillin, 4-fluoronitrobenzene, and 4-amino-3,5-dichloropyridine) was coupled with methanesulfonyl chloride in THF and pyridine to give the sulfonamide II. The latter inhibited the PDE4-induced conversion of [3H] cAMP to the corresponding [3H] 5'-AMP with IC50 of 0.5058 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of immune disorders, inflammatory

Updated Search


conditions, allergic conditions, CNS diseases, and insulin resistant diabetes (no data).

RX(500) OF 523 COMPOSED OF RX(84), RX(85), RX(86), RX(87), RX(88), RX(89),
RX(81)


RX(500) FL + FU + CG + X ==> FH




FL



FU




CG



X

7
STEPS
→



● 2 Na

FH

RX(84) RCT FL 19688-56-3

STAGE(1)

RGT EI 7647-01-0 HCl

SOL 7732-18-5 Water

Updated Search

CON room temperature -> <5 deg C

STAGE(2)

RGT FN 7632-00-0 NaNO2

CON SUBSTAGE(1) <5 deg C

SUBSTAGE(2) 30 minutes, <5 deg C

STAGE(3)

RGT FO 13755-29-8 Na[BF4]

CON SUBSTAGE(1) <5 deg C

SUBSTAGE(2) 30 minutes, <5 deg C

STAGE(4)

RGT FP 7664-93-9 H2SO4, FQ 1317-39-1 Cu2O

SOL 7732-18-5 Water

CON SUBSTAGE(2) 15 - 30 minutes

PRO FM 778577-00-7

RX(85)

RCT FM 778577-00-7

RGT FS 5470-11-1 H2NOH-HCl, BC 1310-73-2 NaOH

PRO FR 778577-01-8

SOL 67-56-1 MeOH, 7732-18-5 Water

CON SUBSTAGE(1) room temperature

SUBSTAGE(2) 6 - 7 hours, reflux

RX(86)

RCT FR 778577-01-8

STAGE(1)

RGT Y 7719-09-7 SOCl2

SOL 109-99-9 THF

CON SUBSTAGE(2) 30 minutes

STAGE(2)

SOL 7732-18-5 Water

PRO FT 778577-02-9

RX(87)

RCT FU 4885-02-3, FT 778577-02-9

STAGE(1)

RGT FW 7646-78-8 SnCl4

SOL 75-09-2 CH2Cl2

CON SUBSTAGE(1) room temperature -> -10 deg C

SUBSTAGE(2) -10 deg C

SUBSTAGE(3) 30 minutes, -10 deg C -> room temperature

STAGE(2)

SOL 7732-18-5 Water

PRO FV 778577-03-0

RX(88)

RCT FV 778577-03-0

RGT FY 7758-19-2 NaOClO, FZ 5329-14-6 Sulfamic acid

PRO FX 778577-04-1

SOL 109-99-9 THF, 7732-18-5 Water

CON SUBSTAGE(1) room temperature

SUBSTAGE(2) 5 minutes, 10 deg C

SUBSTAGE(3) 30 minutes, 10 deg C

RX(89)

RCT CG 543-27-1, FX 778577-04-1

STAGE(1)

RGT DY 7087-68-5 EtN(Pr-i)2
 SOL 68-12-2 DMF
 CON SUBSTAGE(1) room temperature -> -20 deg C
 SUBSTAGE(2) -20 deg C
 SUBSTAGE(3) 10 - 12 hours

STAGE(2)

SOL 7732-18-5 Water

PRO FG 778577-05-2

RX(81) RCT X 22889-78-7, FG 778577-05-2

STAGE(1)

RGT Z 7646-69-7 NaH
 SOL 68-12-2 DMF
 CON SUBSTAGE(2) 30 minutes

STAGE(2)

SOL 7732-18-5 Water

PRO FH 778576-99-1

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 141:140291 CASREACT

TITLE: An efficient route to 6-(het)aryl-2-methyl-2,3-dihydro-1H-pyridin-4-ones as potential nAChRs ligands

AUTHOR(S): Leflemme, Nicolas; Dallemagne, Patrick; Rault, Sylvain

CORPORATE SOURCE: Centre d'Etudes et de Recherche sur le Medicament de Normandie, UFR des Sciences Pharmaceutiques, Caen, 14032, Fr.

SOURCE: Tetrahedron (2004), 60(22), 4861-4865

CODEN: TETRAB; ISSN: 0040-4020


PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new efficient pathway to synthesize 6-(het)aryl-2-methyl-2,3-dihydro-1H-pyridin-4-ones is described. This reaction sequence involved, as a key step, a Suzuki cross-coupling reaction between various boronic acids and an 6-iodo-2,3-dihydropyridin-4-one. A final deprotecting step furnished the attempted products.

RX(12) OF 46 AF ==> K...



RX(12) RCT AF 1072-97-5

STAGE(1)

RGT AG 7632-00-0 NaNO₂, E 7647-01-0 HCl

CON 0 deg C

STAGE(2)

RGT AH 7758-89-6 CuCl

CON 0 deg C -> room temperature

PRO K 53939-30-3

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 140:163819 CASREACT

TITLE: Synthesis of pyrido and pyrazinodithienodipyrimidine-
4,8(3H,9H)-dione derivatives by the aza-Wittig
methodology

AUTHOR(S): Vilarelle, David Vazquez; Veira, Carlos Peinador;
Quintela Lopez, Jose M.

CORPORATE SOURCE: Facultad de Ciencias, Departamento de Quimica
Fundamental, Universidad de La Coruna, La Coruna,
E-15071, Spain

SOURCE: Tetrahedron (2004), 60(2), 275-283


CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



AB A one-pot synthesis of the hitherto unreported pyrido[5'',6'':4,5;
3''2'':4',5']dithieno[3,2-d:3',2'-d']dipyrimidine-4,8(3H,9H)-diones, e.g.
I (X = CH), and pyrazino[5'',6'':4,5;3''2'':4',5']dithieno[3,2-d:3',2'-
d']dipyrimidine-4,8(3H,9H)-diones, e.g. I (X = N) pentaheterocyclic
systems, based on the tandem aza-Wittig heterocumulene-mediated annulation
strategy, is described.

RX(1) OF 157 A ==> B...

Updated Search



RX(1) RCT A 51768-01-5

STAGE(1)

RGT C 7447-39-4 CuCl₂, D 110-46-3 Isoamyl
 nitrite
 SOL 75-05-8 MeCN
 CON 5 hours, 65 deg C

STAGE(2)

RGT E 7647-01-0 HCl
 SOL 7732-18-5 Water
 CON room temperature, acidify

PRO B 151229-84-4

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 140:93833 CASREACT

TITLE: An Efficient Two-Step Total Synthesis of the
 Quaterpyridine Nemertelline

AUTHOR(S): Bouillon, Alexandre; Voisin, Anne Sophie; Robic,
 Audrey; Lancelot, Jean-Charles; Collot, Valerie;
 Rault, Sylvain

CORPORATE SOURCE: UFR des Sciences Pharmaceutiques, Centre d'Etudes et de
 Recherche sur le Medicament de Normandie, Caen, 14032,
 Fr.

SOURCE: Journal of Organic Chemistry (2003), 68(26),
 10178-10180


CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



The diagram illustrates a chemical reaction scheme. On the left is the starting material, 2-chloro-4-amino-6-hydroxypyridine, labeled 'H'. It is a pyridine ring with a chlorine atom at position 2, an amino group (H₂N) at position 4, and a hydroxyl group (H) at position 6. Asterisks are placed next to the amino and hydroxyl groups. An arrow points to the right, labeled '2 STEPS'. On the right is the product, 2-chloro-4-bromopyridine, labeled 'W'. It is a pyridine ring with a chlorine atom at position 2 and a bromine atom (Br) at position 4. Asterisks are placed next to the chlorine and bromine atoms.


RX(6) RCT N 52200-48-3

RGT X 4111-54-0 LiN(Pr-i)₂
CAT 7726-95-6 Br₂
CON -78 - -50 deg C

RGT J 7647-01-0 HCl
SOL 7732-18-5 Water

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 7 OF 9 CASREACT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 137:353202 CASREACT
 TITLE: Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2',3'-Disubstituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes: Epibatidine Analogues
 AUTHOR(S): Carroll, F. Ivy; Lee, Jeffrey R.; Navarro, Hernan A.; Ma, Wei; Brieady, Lawrence E.; Abraham, Philip; Damaj, M. I.; Martin, Billy R.
 CORPORATE SOURCE: Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, NC, 27709, USA
 SOURCE: Journal of Medicinal Chemistry (2002), 45(21), 4755-4761
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I

AB A number of 2',3'-disubstituted epibatidine analogs were synthesized and evaluated in vitro for potency at nicotinic acetylcholine receptors (nAChRs) and in vivo for antinociception activity in the tail-flick and hot-plate models of acute pain and for their ability to affect core body temperature. Compds. that possessed electron-withdrawing groups (F, Cl, Br, and I) in both the 2'- and the 3'-positions showed affinities at the nAChR similar to epibatidine. However, in vivo efficacy did not correlate with affinity. 2-Exo-(3'-Amino-2'-chloro-5'-pyridinyl)-7-azabicyclo[2.2.1]heptane (I), an epibatidine analog possessing an electron-releasing amino group in the 3'-position, produced the highest affinity. Compound I was also the most selective epibatidine analog with a K_i of 0.001 nM at $\alpha\beta$ nAChRs, which is 26 times greater than that of epibatidine, and a $\alpha\beta/\alpha\gamma$ K_i ratio of 14 000, twice that of epibatidine. In vivo testing revealed that this compound potentially inhibited nicotine-induced antinociception with AD_{50} values below 1 $\mu\text{g}/\text{kg}$. Surprisingly, this same compound was also an agonist at higher doses (ED_{50} .apprx.20 $\mu\text{g}/\text{kg}$). Thus, the addition of the 3'-amino group to epibatidine confers potent antagonist activity to the compound with little effect on agonist activity. 2,3-Disubstituted epibatidine analogs possessing a 2'-amino group combined with a 3'-bromo or 3'-iodo group showed in vitro and in vivo nAChR properties similar to nicotine.

RX(6) OF 95 ...R ==> W...



RX(6) RCT R 25391-57-5

STAGE(1)

RGT X 7647-01-0 HCl
SOL 7732-18-5 Water

STAGE(2)

RGT D 7632-00-0 NaNO₂, Y 7758-89-6 CuCl

STAGE(3)

RGT E 1336-21-6 NH₄OH
SOL 7732-18-5 Water

PRO W 426463-05-0

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 137:125209 CASREACT

TITLE: Synthesis of novel halopyridinylboronic acids and
esters. Part 1: 6-Halopyridin-3-yl-boronic acids and
esters

AUTHOR(S): Bouillon, Alexandre; Lancelot, Jean-Charles; Collot,
Valerie; Bovy, Philippe R.; Rault, Sylvain

CORPORATE SOURCE: Centre d'Etudes et de Recherche sur le Medicament de
Normandie, UFR des Sciences Pharmaceutiques,
Universite de Caen, Caen, 14032, Fr.

SOURCE: Tetrahedron (2002), 58(14), 2885-2890
CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.


DOCUMENT TYPE: Journal

LANGUAGE: English

AB This paper describes a general method for the synthesis and isolation of
novel 6-halo-pyridin-3-yl-boronic acids and esters. These compds. are
prepared taking in account a regioselective halogen-metal exchange with a
trialkyl borate starting from 2,5-dihalopyridines. All substrates studied
to date provided a single regioisomeric boronic acid or ester product.
Addnl., these compds. have been found to undergo Pd-catalyzed coupling
with a range of aryl halides and authorize a strategy to produce new
pyridines libraries. Thus, lithiation of 2,5-dibromopyridine with BuLi in
Et₂O followed by borylation with B(OiPr)₃ and sequential basic hydrolysis
gave 75% 2-bromo-5-pyridylboronic acid.

RX(4) OF 24 M ==> I...

Updated Search



RX(4) RCT M 1072-97-5
 RGT F 7647-01-0 HCl, N 7632-00-0 NaNO₂, O
 7758-89-6 CuCl
 PRO I 53939-30-3
 SOL 7732-18-5 Water

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 135:107263 CASREACT

TITLE: Synthesis of multifunctional ligands: a
 2,9-diaryl-1,10-phenanthroline/2,2':6',2''-terpyridine
 conjugate

AUTHOR(S): Belfrekh, N.; Dietrich-Buchecker, C.; Sauvage, J.-P.

CORPORATE SOURCE: Laboratoire de Chimie Organo-Minérale, Faculté de
 Chimie, rue Blaise Pascal, 4, UMR 7513 du CNRS,
 Université Louis Pasteur, Strasbourg, 67070, Fr.

SOURCE: Tetrahedron Letters (2001), 42(15), 2779-2781

CODEN: TELEAY; ISSN: 0040-4039


PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis of a ligand including a 1,10-phenanthroline and a
 2,2':6',2''-terpyridine separated by a 1,3-phenylene spacer is presented. The
 different aromatic C-C bonds were generated by reactions with organolithium
 compds., and by Stille and Suzuki couplings.

RX(1) OF 44 A ==> B...



RX(1) RCT A 1072-97-5

STAGE(1)

RGT C 7647-01-0 HCl, D 7632-00-0 NaNO₂

SOL 7732-18-5 Water

STAGE(2)

Updated Search

RGT E 7758-89-6 CuCl

PRO B 53939-30-3

NTE literature prepn.


REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

ACCESSION NUMBER: 137:125209 CASREACT
 TITLE: Synthesis of novel halopyridinylboronic acids and esters. Part 1: 6-Halopyridin-3-yl-boronic acids and esters
 AUTHOR(S): Bouillon, Alexandre; Lancelot, Jean-Charles; Collot, Valerie; Bovy, Philippe R.; Rault, Sylvain
 CORPORATE SOURCE: Centre d'Etudes et de Recherche sur le Medicament de Normandie, UFR des Sciences Pharmaceutiques, Universite de Caen, Caen, 14032, Fr.
 SOURCE: Tetrahedron (2002), 58(14), 2885-2890
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB This paper describes a general method for the synthesis and isolation of novel 6-halo-pyridin-3-yl-boronic acids and esters. These compds. are prepared taking in account a regioselective halogen-metal exchange with a trialkyl borate starting from 2,5-dihalopyridines. All substrates studied to date provided a single regioisomeric boronic acid or ester product. Addnl., these compds. have been found to undergo Pd-catalyzed coupling with a range of aryl halides and authorize a strategy to produce new pyridines libraries. Thus, lithiation of 2,5-dibromopyridine with BuLi in Et₂O followed by borylation with B(OiPr)₃ and sequential basic hydrolysis gave 75% 2-bromo-5-pyridylboronic acid.

RX(4) OF 24 M ==> I...



RX(4) RCT M 1072-97-5
 RGT F 7647-01-0 HCl, N 7632-00-0 NaNO₂, O
 7758-89-6 CuCl
 PRO I 53939-30-3
 SOL 7732-18-5 Water

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CASREACT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 135:107263 CASREACT

TITLE: Synthesis of multifunctional ligands: a
2,9-diaryl-1,10-phenanthroline/2,2':6',2''-terpyridine
conjugate

AUTHOR(S): Belfrek, N.; Dietrich-Buchecker, C.; Sauvage, J.-P.

CORPORATE SOURCE: Laboratoire de Chimie Organo-Minérale, Faculté de
Chimie, rue Blaise Pascal, 4, UMR 7513 du CNRS,
Université Louis Pasteur, Strasbourg, 67070, Fr.

SOURCE: Tetrahedron Letters (2001), 42(15), 2779-2781

CODEN: TELEAY; ISSN: 0040-4039


PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis of a ligand including a 1,10-phenanthroline and a
2,2':6',2''-terpyridine separated by a 1,3-phenylene spacer is presented. The
different aromatic C-C bonds were generated by reactions with organolithium
comps., and by Stille and Suzuki couplings.

RX(1) OF 44 A ==> B...



RX(1) RCT A 1072-97-5

STAGE(1)

RGT C 7647-01-0 HCl, D 7632-00-0 NaNO2

SOL 7732-18-5 Water

STAGE(2)

RGT E 7758-89-6 CuCl

PRO B 53939-30-3

NTE literature prepn.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>